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Guide to presenting clinical prediction models for use in clinical 
settings
Laura J Bonnett,1 Kym I E Snell,2 Gary S Collins,3 Richard D Riley2
Clinical prediction models estimate the 
risk of existing disease or future 
outcome for an individual, which is 
conditional on the values of multiple 
predictors such as age, sex, and 
biomarkers. In this article, Bonnett and 
colleagues provide a guide to 
presenting clinical prediction models 
so that they can be implemented in 
practice, if appropriate. They describe 
how to create four presentation 
formats and discuss the advantages 
and disadvantages of each format. A 
key message is the need for 
stakeholder engagement to determine 
the best presentation option in relation 
to the clinical context of use and the 
intended users
Introduction
Clinical prediction models estimate the risk of 
existing disease (diagnostic prediction model) or 
future outcome (prognostic prediction model) for 
an individual, which is conditional on the values of 
multiple predictors (prognostic or risk factors) such as 
age, sex, and biomarkers.1 A large number of prediction 
models are published in the medical literature each 
year,2 and most are developed using a regression 
framework such as logistic and Cox regression (box 
1). Prediction models are also known as risk scores, 
prognostic indices, or prognostic scores. Examples 
include the Framingham risk score, which predicts 10 
year risk of coronary heart disease,3 and the APACHE 
(acute physiological assessment and chronic health 
evaluation) scores for mortality after admission to an 
intensive care unit.4 5
The transparent reporting of a multivariable 
prediction model for individual prognosis or diagnosis 
(TRIPOD) statement provides guidance on key 
information for authors to report when developing 
or validating prediction models.6 7 Although the 
TRIPOD statement highlights the importance of the 
presentation of models, relatively little information or 
practical guidance exists on how to actually present 
a prediction model for use after development—for 
example, to aid implementation in clinical settings, if 
appropriate. A key resource is chapter 18 in the book 
by Steyerberg.8
When choosing the format to present a prediction 
model, researchers should carefully consider the 
intended users, settings, and timing of use. It is helpful 
to ask: “who will be accessing the model in this 
format, and when and in what setting will they use it?” 
The presentation can then be formatted accordingly. 
Fundamentally, the full model equation should 
always be presented in the journal article6 7; this is 
essential to enable independent external validation. 
However, additional presentation formats might be 
required, perhaps outside of the journal article, to 
enable healthcare professionals to use the model 
in a particular clinical setting (eg, when access to 
computers or mobile devices is limited). Similarly, the 
format might need tailoring for lay people when using 
the model at home (eg, patients with asthma deciding 
on appropriate management of their condition using 
Asthma UK’s asthma attack risk checker9) to improve 
shared decision making.10 User groups can help 
guide the best presentation choices in each situation, 
including healthcare professionals, patients, and the 
public. Patient and public involvement groups and 
focus groups are useful arenas for this; they highlight 
the need for participant and public information and 
engagement within health research.
Alongside the full model equation, a range of 
presentation formats might be required that differ 
according to several factors: the medium by which they 
are presented (paper versus electronic), the setting 
in which the models are to be applied (eg, clinic, 
bedside, or at home), the level of detail required in the 
predictions (eg, approximate or rounded risk estimates, 
or exact risk estimates), and user friendliness (simple 
to complex formats).8 In this paper, we summarise four 
key ways of presenting clinical prediction models that 
could aid their use in clinical practice, if appropriate. 
We outline how to create each format and describe their 
advantages and disadvantages in relation to the clinical 
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Summary poIntS
•   Presentation format for clinical prediction models deemed suitable for use is 
important but receives relatively limited attention in the literature
•   Clear presentation of a prediction model is fundamental to ensure other 
researchers can independently validate the model, and that healthcare 
professionals and others can implement it within healthcare
•   Presentation of the full model equation is essential. There are many ways 
to present prediction models for end users, which range from points score 
systems and nomograms, to websites and mobile apps
•   The best presentation is user and environment specific, and it is preferably 
determined through engagement of stakeholders, including patients
•   If presentation requires a simplified version of the full model to be generated, 
then the predictive performance of this simplified model should also be 
validated and compared with that of the full model
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context of use, and the intended user. Table 1 provides 
an overview of the different presentation formats.
Our article is not about how to develop or validate a 
prediction model,8 11 or how to decide if it is fit for clinical 
use1 12; rather, we assume a model has been developed 
and has been deemed potentially useful for clinical 
practice, and so the researcher needs to consider how 
to present the model to aid implementation. For this 
purpose we use the model shown in box 2 to illustrate 
how to predict mortality risk over time in patients 
with a diagnosis of primary biliary cirrhosis. This 
survival model is used throughout the article, but the 
presentation formats described also apply to other risk 
prediction models developed using regression, such as 
those derived using logistic regression. Many of these 
models are relevant for prediction of a continuous 
outcome (eg, using linear regression).
presentation using a points score system
Description
Within points score systems, points are assigned based 
on the predictor values for an individual. The total 
points score is then mapped to a corresponding risk of 
event or survival probability.21 The intended users for 
points score systems are healthcare professionals and 
patients. These systems can be presented on a screen 
(eg, monitor, tablet) as part of a consultation, printed 
off as a take home sheet for patients, or used on the 
wards as a reference guide.
How to derive a points score system
To produce a points score system, a prediction model 
is first developed (eg, using logistic or Cox regression; 
see boxes 1 and 2), and then the regression coefficients 
of included predictors are assigned integer scores, 
which can be negative or positive. Unfortunately, any 
continuous predictors need to be categorised, and so 
some predictive accuracy is sacrificed. Categories do 
not need to be of equal size, and by having unequal 
categories non-linearity can be more appropriately 
handled. The steps to develop a points score system 
can be summarised:
1. Organise the continuous predictors into categories 
and determine the midpoint for each category.
2. Choose a reference category for each predictor 
(continuous, binary, and categorical).
3. For continuous variables, determine how far 
each category is from the reference category, and then 
multiply each difference by the regression coefficient 
for that predictor to determine the difference in 
“regression units.” For binary and categorical 
variables, the “regression unit” is simply the regression 
coefficient for that predictor.
4. Define the number of regression units that will 
correspond to 1 point in the points scoring system; this 
definition is usually based on clinician preference.
5. Determine the points (rounded to the nearest 
integer) associated with each of the categories of the 
predictors.
6. Determine the minimum and maximum possible 
points totals.
7. Calculate the risk estimate for each points total 
across the range by using the original model with 
the points scores (rounded) to get the predicted 
probabilities. This estimate is essentially a new risk 
prediction model that approximates the full model.
Note that sometimes scores are derived based 
on hazard ratios or odds ratios rather than the 
corresponding regression coefficients. This approach 
is mathematically inappropriate as Cox (or logistic) 
regression models assume additivity of the log hazard 
(or log odds) ratios.22
Alongside the point score system, it is important to 
also present the accompanying table of probabilities 
(absolute risk predictions) to allow the points score 
to be translated to a predicted risk. Decisions such as 
low, intermediate, or high risk only based on a points 
total are uninformative unless it is clear how these 
decisions are defined on the predicted absolute risk 
scale.
A full worked example is provided in the appendix. 
Also, see Sullivan and colleagues for further details, 
including the mathematical formula associating the 
risk of outcome with each possible total points score 
for logistic and survival regression models.21
Advantages and disadvantages
Points score systems are easy to understand after 
an initial explanation or demonstration, and so 
instructions on their use should be given alongside 
these systems. Depending on the complexity of 
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Box 1: Typical format of prediction models developed using regression to enable risk predictions in new 
individuals (adapted from Riley and colleagues17)
Short term clinical prediction models or diagnostic models
If the outcome can take one of only two options (eg, death or presence of the disease) and is known for all 
patients at a particular time, a prediction model can be developed using logistic regression. This has the 
following form:
where p is the probability of having the outcome and ln(p/1–p) is the log odds of the outcome; α is the 
intercept term and the baseline log odds where “baseline” refers to those whose X values are zero. If all X 
predictors are centred at the mean, α is the log odds for someone with average X values. The X terms denote 
values of included predictors so that X
1
 might represent the age of the patient in years, X
2
 might represent sex 
and be 1 for men and 0 for women, etc. The β terms denote the change in log odds (otherwise known as the 
log odds ratio) for each one unit increase in the corresponding predictor. For example, β
1
 might be the increase 
in the log odds for each one year increase in age, and β
2
 might be the increase in the log odds for a man 
compared with a woman. Risk (outcome probability) predictions, p for a new individual can be estimated by 
inputting his or her predictor values into the equation and then transforming back to the probability scale:
Clinical prediction models over time
If risks are predicted over time, or at a time point when some people in the dataset have previously dropped 
out or been lost to follow-up (that is, censored), a prediction model can be developed using a survival model; 
for example, a Cox model or a parametric survival model. This has the following form:
h(t) is the hazard rate of the outcome at time t and h
0
(t) is the baseline hazard rate. The X terms denote values 
of included predictors, and each β denotes the change in log hazard rate (otherwise known as the log hazard 
ratio) for each one unit increase in the corresponding predictor. “Baseline” refers to people whose X values are 
zero, or if all predictors are centred at the mean, the underlying hazard rate for someone with average X values.
Predictions of not having the outcome at time t (“survival” probability) for a new individual can be obtained by 
inputting their predictor values into the equation and then transforming back to the probability scale:
where S
0
(t) is the baseline survival probability at time t. Conversely, risk predictions (outcome probability) for 
having the outcome at time t for a new individual can be calculated as:
h
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the model, and the number of included predictors, 
paper based point score systems can enable risks to 
be estimated quicker than directly inputting patient 
values into an online calculator or published model. 
However, the predictions of risk (or survival) are only 
approximations of the actual predicted risk from the 
full model; this is because information on continuous 
predictor values is discarded by categorisation, and 
regression units are rounded. Researchers must always 
check that the predictive performance of the simplified 
model based on a points score system is similar to (and 
has the same potential clinical impact as) the original 
full model.
Application
Tables 3a and b illustrate a points score system for 
the primary biliary cirrhosis example. In table 3a, 
scores are assigned to categories of each predictor, 
which have been scaled according to a 15 year 
increase in age (that is, the regression coefficient for 
age multiplied by 15); table 3b presents probabilities 
of the outcome that correspond to the points total. 
For example, an individual aged 55 (0 points), with 
cirrhosis (3 points), albumin of 34.4 g/dL (0 points), 
and central cholestasis (5 points) has a points total of 
8; this corresponds to a probability of death of 0.46 
at one year and 0.90 at three years. These figures 
are similar to the equivalent estimates of 0.44 and 
0.89 for the risk of death at one and three years, 
respectively, directly obtained from the full model 
equation for this individual. These data suggest that 
the simplification led to only small changes in risk 
predictions from the points score system for this 
individual.
Table 1 | Examples of formats for presenting clinical prediction models to enable outcome risks to be calculated for new individuals; these should be 
considered after presenting the full model equation
Presentation 
format Explanation Advantages Disadvantages Example
Points score 
system
Comprises two tables: one enables 
a total points score to be calculat-
ed based on predictor values; other 
provides estimate of risk based on 
total points score
Easy to understand
Predictions are approximate. Need predictions at 
each time point of interest for survival outcomes. 
Continuous predictors must be categorised
Renal artery 
stenosis13
Graphical score 
chart
Graphical representation of highly 
simplified points score system Easy to understand
Can only accommodate limited number of  predictors. 
Need one for each time point of  interest for survival 
outcomes. Prediction of range of event probabilities 
and thus  predictions are approximate. Continuous 
 predictors must be categorised
Traumatic  
bleeding14
Nomogram
Graphical presentation of predic-
tion model: points are assigned 
based on predictor values that are 
then summed and translated to 
estimate of risk of outcome
Can easily be applied away from computer (eg, 
community based medicine)
Can initially be difficult to understand. Could be 
inaccurate depending on size and resolution of 
published nomogram
Prostate cancer,15 
coronary heart 
disease16
Websites and 
applications
Interactive graphical user interface 
that provides risk estimates 
from underlying (often hidden) 
prediction model after user inputs 
predictor values
Visually appealing to intended users. Can 
automate complex modelling methods in back-
ground. Full equation is retained (albeit in back-
ground). Can quickly produce risk predictions at 
multiple time points for  survival outcomes. Can 
automate extraction of predictor values (eg, from 
e-health records, or from available hardware 
such as GPS coordinates, calendar time, blood 
pressure)
Easy access could lead to overuse or access by 
those who might not be target population. Can be 
created by anyone so no guarantee model has been 
developed well. Often difficult to know how model 
equation has been translated to graphical tool. Often 
unclear whether it is of relevance or has been validat-
ed in relevant population. Possible privacy and data 
storage issues. Model could change over time and by 
location without changes being tracked
Breast cancer10
Continuous
predictor
Age (years)
Albumin (g/dL)
25.0-78.0
20.0-56.5
54.8 (10.6)
34.4 (5.9)
Cirrhosis
Central cholestasis
Treatment
No: 0, yes: 1
No: 0, yes: 1
Azathioprine: 0,
placebo: 1
148 (71.5), 59 (28.5)
170 (82.1), 37 (17.9)
109 (52.7), 98 (47.3)
Range Mean
(SD)
Binary
predictor
Coding No (%)
LP
i
 = (0.02 x (age – 54.8)) + (1.06 x (cirrhosis – 0.285)) +
(-0.06 x (albumin – 34.4)) + (1.59 x (cholestasis – 0.179)) +
(0.31 x treatment)
exp (LP
i
 )
1 – S (t) = 1 – S
0
(t)
Box 2: Dataset and prediction model for primary biliary cirrhosis
Clinical context
These data are from an international trial on the therapeutic effect of the immunosuppressant drug 
azathioprine in primary biliary cirrhosis (also known as primary biliary cholangitis) of the liver and are publicly 
available.18 19 Primary biliary cirrhosis is an autoimmune condition that can get worse over time and without 
treatment might lead to liver failure. 248 patients with primary biliary cirrhosis met eligibility criteria for the 
randomised placebo controlled trial, of whom 127 received the intervention and 121 the placebo. 57 (45%) 
deaths occurred in the treatment group and 62 (51%) in the control group. Risk prediction is important to 
guide patient counselling and potentially inform treatment choice.
Predictors
Predictors of interest were age (years), presence of cirrhosis (yes/no), albumin (g/dL), presence of central 
cholestasis (yes/no), and placebo treatment (rather than azathioprine, yes/no). Table 2 lists the characteristics 
of these predictors, including the ranges of the continuous predictors. Treatment was explicitly modelled.20
Table 2 Patient characteristics for primary biliary cirrhosis running example
Methods to develop model
A Cox proportional hazards regression model was fit to estimate probability of death from primary biliary 
cirrhosis, with all predictor values centred at the mean predictor value in the study. As this was only an 
illustrative example, no adjustment for potential overfitting was made.
Final model equation
The estimated linear predictor (LP) for this model is the linear combination of predictors and their associated 
regression coefficients; that is, for individual i :
The model for probability of death from primary biliary cirrhosis is shown in equation 7. Estimates of baseline 
survival at one year (S
0
(1)) and three years (S
0
(3)) are also provided, based on a Nelson-Aalen type estimator. 
Note that time of predictions is made relevant by clinical and patient stakeholders:
As predictor values are centred, the baseline (S
0
(t)) in this equation relates to the survival probability over time 
for an “average” treated individual whose predictor values equal the mean predictor values in the study. As the 
prediction equation is derived from randomised controlled trial data the treatment effect can be assessed, 
which is in contrast with the more usual case when prediction equations are derived from cohort studies. 
S
0
(1) = 0.930; S
0
(3) = 0.759
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presentation using graphical score chart
Description
Graphical score charts are highly simplified, colour 
coded versions of points score systems. Similar to 
the points score system, a graphical score chart is 
a presentation format for a prediction model, when 
the intended users are healthcare professionals and 
patients. The chart can be used either on screen or as 
a print out. An example of using this approach is the 
SCORE (systematic coronary risk evaluation) model for 
predicting cardiovascular disease.23
How to derive a graphical score chart
The probability of the outcome must be calculated for 
each relevant combination of predictors as described 
in box 1, and is based on the average value of the 
category or the group of individuals in that category 
in the development data. Probabilities can then 
be tabulated and colour coded based on clinically 
important categories of risk. For example, those with 
higher risk predictions (near to 1) could be coded as 
red, and those with low risk predictions (near to 0) 
could be coded as yellow.
Advantages and disadvantages
Graphical score charts are easy to understand and 
the colour coding can increase ease of use compared 
with points score systems.14 Additionally, decision 
guidelines can be coupled to the predictions; for 
example, dark red implies referral to intensive care. 
This coupling enables the rapid stratification of 
patients. Choosing decision thresholds needs careful 
thought and evaluation; in particular, arbitrary cut-off 
values should be avoided.24
This presentation usually requires some 
simplification of the model because it can only 
accommodate a limited number of predictors and 
requires continuous predictors to be presented as 
categories. Loss of information about predicted risks 
also occurs because the results are typically presented 
as ranges of predicted risks rather than specific values. 
Each time point of interest requires its own graphical 
score chart, which is a further disadvantage. Similar 
to the points score system, the simplified model based 
on a score chart should be checked for its predictive 
performance (at each time point of interest) compared 
with the full model.
Application
Figure 1 shows a graphical score chart for the primary 
biliary cirrhosis example. The chart was created using 
the point score system shown in tables 3a and b. Risks 
of death of widths 0.1 might be considered clinically 
meaningful for example, up until 0.3, and were thus 
chosen as the four colour categories. According to this 
chart, risk of death at one year is 0.46 for a patient who 
is aged 55, has cirrhosis, central cholestasis, albumin 
of 34.4 g/dL, and been treated with azathioprine. This 
predicted risk is similar to the value of 0.44 estimated 
from the full model.
presentation using a nomogram
Description
Nomograms are another graphical presentation format 
for a clinical prediction model (fig 2). Similar to the 
points score system, points are assigned based on the 
predictor values for a particular individual, which are 
then equated to a risk of event or survival probability.25 
The intended users of a nomogram are healthcare 
professionals. Nomograms are best used as reference 
guides, potentially on wards or during consultations. 
Similar to graphical score charts, nomograms can be 
colour coded to aid interpretation.26
Table 3b
Points total
Probability of death
At 1 year At 3 years
−6 0.008 0.029
−5 0.011 0.040
−4 0.014 0.054
−3 0.020 0.073
−2 0.027 0.098
−1 0.036 0.131
0 0.049 0.175
1 0.067 0.231
2 0.090 0.301
3 0.121 0.387
4 0.161 0.487
5 0.213 0.598
6 0.280 0.712
7 0.361 0.818
8 0.458 0.902
9 0.566 0.958
10 0.681 0.987
11 0.790 0.997
12 0.881 1.000
Table 3a | Points score system for probability of death 
for new patients with primary biliary cirrhosis based on 
model derived in box 2
Predictor categories Points Age (years):
 25-34 −2
 35-44 −1
 45-54 −1
 55-64 0
 65-78 1
Cirrhosis:
 No 0
 Yes 3
Albumin (g/dL):
 20.0-24.9 2
 25.0-29.9 1
 30.0-34.9 0
 35.0-39.9 −1
 40.0-44.9 −2
 45.0-49.9 −3
 50.0-56.5 −4
Central cholestasis:
 No 0
 Yes 5
Treatment:
 Azathioprine 0
 Placebo 1
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How to derive a nomogram
The steps to build a nomogram are:
1. For each predictor, calculate the maximum 
change in the developed model’s linear predictor by 
multiplying the predictor’s regression coefficient by the 
difference between the maximum and minimum value 
of the predictor in the dataset. Order the predictors by 
their calculated maximum change.
2. Assign up to 100 points for each predictor. First 
assign 100 points to the predictor with the largest 
maximum change as identified from step 1. Call 
this predictor A. Then provide a points score for the 
other predictors equal to 100×(maximum change for 
predictor/maximum change for predictor A).
3. Calculate the minimum and maximum possible 
total points based on all possible combinations of 
predictors; project the points onto the probability scale 
by fitting a prediction model as in box 1 with total 
points as the only predictor.
Nomograms can be drawn using statistical software 
programmes such as R (through Harrell’s “rms” 
package) and Stata (by using “nomolog” for logistic 
regression and “nomocox” for Cox regression).27 28
Advantages and disadvantages
The main advantages of nomograms over the other 
presentation formats is that continuous predictors do 
not need to be categorised, and multiple time points 
can be included in a single nomogram by incorporating 
multiple probability scales based on the possible 
total points. Additionally, the relative importance of 
predictors can be judged by the length of the lines within 
the nomogram. Furthermore, interaction and non-
linear terms can be well handled.8 Complex models, 
for example those with time dependent predictors, can 
also be presented in this way.29 Nomograms can easily 
be applied away from a computer, especially when a 
model includes only a small number of predictors.
Nomograms can, however, appear relatively complex 
at first sight and they require an explanation as to 
how they should be used (highlighted in the TRIPOD 
statement6). Additionally, they can be inaccurate 
depending on the size and resolution of the published 
figure; the larger the number of predictors included 
in the model, the more challenging the nomogram is 
to interpret. Rounding of coefficients might also be 
required.
No25
to
35
20
to
25
25
to
30
Albumin (g/dL)
No central cholestasisAzathioprine
treatment
Probability of death at 1 year
30
to
35
35
to
40
40
to
45
45
to
50
≥50
20
to
25
25
to
30
Albumin (g/dL)
Central cholestasis
30
to
35
35
to
40
40
to
45
45
to
50
≥50
0.05 0.04 0.03 0.02 0.01 0.01 0.01 0.21 0.16 0.12 0.09 0.07 0.05 0.04
Yes 0.12 0.09 0.07 0.05 0.04 0.03 0.02 0.46 0.36 0.28 0.21 0.16 0.12 0.09
No35
to
45
0.07 0.05 0.04 0.03 0.02 0.01 0.01 0.28 0.21 0.16 0.12 0.09 0.07 0.05
Yes 0.16 0.12 0.09 0.07 0.05 0.04 0.03 0.57 0.46 0.36 0.28 0.21 0.16 0.12
0.07 0.05 0.04 0.03 0.02 0.01 0.01 0.28 0.21 0.16 0.12 0.09
0.0-0.1 0.1-0.2 0.2-0.3 >0.3
0.07 0.05
0.16 0.12 0.09 0.07 0.05 0.04 0.03 0.57 0.46 0.36 0.28 0.21 0.16 0.12
No45
to
55 Yes
No55
to
65
0.09 0.07 0.05 0.04 0.03 0.02 0.01 0.36 0.28 0.21 0.16 0.12 0.09 0.07
Yes 0.21 0.16 0.12 0.09 0.07 0.05 0.04 0.68 0.57 0.46 0.36 0.28 0.21 0.16
No
≥65
Cirr.
Age
(years)
0.12 0.09 0.07 0.05 0.04 0.03 0.02 0.46 0.36 0.28 0.21 0.16 0.12 0.09
Yes 0.28 0.21 0.16 0.12 0.09 0.07 0.05 0.79 0.68 0.57 0.46 0.36 0.28 0.21
Fig 1 | Graphical score chart for probability of death for new patients with primary biliary cirrhosis (cirr) based on 
model derived in box 2 and restricted to patients receiving azathioprine treatment
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Application
Figure 2 shows the nomogram associated with the 
primary biliary cirrhosis example from box 2. To 
determine the survival probability at a specified time 
point, the user identifies the points score associated 
with each predictor value by reading up from that 
predictor value to the points scale at the top. Once a 
score has been assigned to each predictor value, a 
total points score is calculated. Translation from total 
points to the probability of the outcome is then made 
by reading down to the associated probability of the 
outcome from the total points scale. Therefore, using 
figure 2, it can be seen that an individual aged 55 (24 
points), with cirrhosis (42 points), albumin of 34.4 g/
dL (65 points), and central cholestasis (62 points), and 
who has been treated with azathioprine (0 points) has 
a total points score of 193. This equates to a one year 
and three year probability of death of 0.40 and 0.85, 
respectively, which are again similar to the estimates 
of 0.44 and 0.89 obtained directly from the full 
regression model. If the individual was not treated (32 
points), but all other characteristics were unchanged, 
the total points score would be 171, which equates to 
a one year and three year probability of death of 0.25 
and 0.68, respectively.
presentation within websites and mobile apps
Description
Increasingly, prediction models are being made 
available through a website calculator or within an app 
for a tablet or smartphone device. These calculators 
and apps are generally interactive graphical user 
interfaces that provide individualised risk estimates 
from an underlying prediction model, which are 
conditional on the user’s inputted predictor values. 
Often access is free, but sometimes a fee is charged.
How to develop a website
Websites are developed using a building platform 
or content management system; they also require 
a domain name and web host. A variety of website 
building platforms exist, including specific tools 
that enable statistical software packages to run web 
apps—for example, Shiny for R and SWire for Stata.30 31 
Websites and apps are available to healthcare 
professionals and the public, and they can be used 
by interested individuals from anywhere in the world. 
These websites and apps can also be designed for use 
in specific circumstances, such as requiring log in 
details from registered users, or through a National 
Health Service server to ensure that the information 
is delivered to the patient through a healthcare 
professional.
Websites need to be explicit about the target user 
and target population, and any website or app should 
clearly state how to use the model. References to 
manuscripts describing the model development and 
subsequent validation (and potentially clinical impact 
evaluation) should also be provided. The website or 
app calculator should be checked to ensure that the 
predicted probability agrees with the predictions from 
the underlying regression model. For models with 
continuous predictors, entering values outside the 
range (of the development dataset) should also be 
restricted to avoid extrapolation, or at least provide a 
warning to the user.
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Fig 2 | Nomogram enabling calculation of predicted probabilities of death at one year and three years for new patients 
with primary biliary cirrhosis. The underlying statistical model is described in box 2
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Advantages and disadvantages
A major advantage is that the full model equation 
can be embedded behind the scenes, and thus no 
approximation is required, and any complexity is 
“hidden” from the end user. Websites and apps can 
provide a user friendly interface in front of complex 
statistical models, which include large numbers 
of predictors, non-linear terms, and interactions. 
Additionally, much of the data input can be 
automated; for example, in general practice the age 
and sex of patients are probably already recorded 
in the medical centre’s computer system. Prediction 
models can be implemented within electronic health 
records to provide real time feedback to clinicians, 
although missing data and implausible values might 
be problematic. Digital applications easily enable 
switching between units for laboratory results and 
anthropometrics, such as height recorded in either 
metres or feet.
Because anyone can create a web calculator, there 
is currently no assurance that the underlying model is 
appropriate for use, has been developed adequately, 
or is validated for the relevant populations accessing 
the website.32 Additionally, it is often difficult to know 
how the model has been translated into the graphical 
tool. Furthermore, the target user (eg, healthcare 
professionals or patients) might not be clear, and 
public access websites could lead to overuse or access 
by people for whom the model is not intended.
Clearly, access to the internet is required. Data privacy 
and storage can be a concern, particularly if a website 
is designed to collect and present data; this concern 
should be clearly signposted on the website or app. 
Furthermore, accompanying graphical presentations 
such as colour coded stick men, smiley faces, or 
similar, to show the proportion of people predicted 
to have the outcome depend on the target user and 
need to be carefully considered.33 34 Beside graphical 
presentations, many other metrics can be used in 
risk communication derived from prediction models. 
An example is the heart age metric recommended by 
the European Society of Cardiology.35 36 Finally, the 
model might be updated over time to reflect changes 
in the underlying population characteristics. The web 
address could also change. Sometimes these changes 
might not have been tracked. Version control is 
therefore vital and the reasons for any model update 
recorded. These changes should be clearly signposted 
on the website.
Application
An example of a website is Your Heart Forecast tool from 
New Zealand.37 This tool provides a graphic design 
that compares a patient’s predicted cardiovascular 
disease risk with that of the healthy population of 
the same age. Because risk can be hard for patients to 
understand, the model provides a graphical depiction 
of heart age and a future projection that depends on 
whether the individual does or does not modify their 
predictors. Other examples include GRACE (for acute 
coronary events),38 ASCVS Plus (for atherosclerotic 
cardiovascular disease),39 and Predict (for breast 
cancer).10 Two examples of websites for primary biliary 
cirrhosis, but with different predictors than those 
in this article’s running example, are UK-PBC40 and 
GLOBE.41
Summary
The format of presentation is an important 
consideration when a clinical prediction model 
is deemed suitable for use in clinical practice. In 
addition to providing the full equation (which is 
essential), there are many ways to present models to 
aid clinical use, ranging from points score systems and 
nomograms, to websites and mobile apps. If a model 
is to be presented in a reduced format (eg, predictors 
based on categorised values even though they were 
originally continuous in the full model), this reduced 
model should undergo the same validation process 
as the full model before it can be deemed suitable for 
clinical use.
The best format is user and environment specific, 
with bedside tools for healthcare professionals 
requiring different options than patients at home 
on a computer or tablet. For this reason, means of 
presentation are best determined through stakeholder 
engagement, including healthcare professionals 
and patients. Empirical evidence is now required to 
determine whether certain formats promote better 
uptake, use, or understanding. In due course, a similar 
guide will be required for models developed using 
advanced or alternative modelling techniques, such as 
landmarking and machine learning.
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